Larry Dobrow

Most Recent Articles by Larry Dobrow

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Bolstered by new data, Radius Health focuses on unmet needs in the osteoporosis market

Only one new osteoporosis drug has been approved over the last six years.

PBMs push forward toward outcomes-based pricing, despite challenges

PBMs push forward toward outcomes-based pricing, despite challenges

The implementation of a broad outcomes-based pricing scheme is a wildly, almost gratuitously complicated project.

Avanir marketing chief on selling first-in-class therapies

Avanir marketing chief on selling first-in-class therapies

Avanir's success with Nuedexta sparked the attention of several suitors. In 2014 the company reached a deal to be sold to Otsuka Pharmaceutical for around $3.5 billion

Leadership Exchange: Engaging the Millennial Doctor

Leadership Exchange: Engaging the Millennial Doctor

In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

More Articles by Larry Dobrow

OPINION

Email Newsletters